About us

Coronavirus (COVID-19)

Coronavirus (COVID-19)

Effects of the coronavirus on the availability of medicines are being closely monitored

Based on the information received by Fimea from pharmaceutical companies, the coronavirus (COVID-19) has so far not caused any major problems in the availability of medicines. Finnish healthcare and pharmaceutical operators are constantly working in close cooperation to prevent shortages so as to avoid problems from arising even if the situation is prolonged.

Together with pharmaceutical manufacturers and importers, Fimea has assessed the production effects of the COVID-19 epidemic and the situation of supply chains and stocks. Fimea has urged operators to carry out risk assessments and to prepare for the escalation and prolongation of the epidemic. Fimea has also provided pharmacies with instructions for customer service situations and advised them to always check the latest information from official sources.

The authorities are actively monitoring the situation in collaboration with other operators in the sector. Information about the situation is also regularly updated between European medicinal authorities.

Fimea publishes the shortages notified by marketing authorisation holders on a website where a search engine for shortages is also available.

Fimea advises against overstocking medicine

Further information about the corona virus

On the Finnish Institute for Health and Welfare website:

Frequently asked questions about the coronavirus (Finnish Institute for Health and Welfare)

Latest updates on the coronavirus epidemic (Finnish Institute for Health and Welfare)

On the EMA website:

Addressing the potential impact of novel coronavirus disease (COVID-19) on medicines supply in the EU (News 10/03/2020)

Coronavirus disease (COVID-19)

On the Ministry of Social Affairs and Health website:

Preparedness for the coronavirus

Read more:

Mandatory reserve supplies